User profiles for Javier Rodríguez-Martorell
Javier Rodriguez MartorellFEA de Hematología (Hemostasia) Hosp. Univ. Virgen del Rocío, Sevilla Verified email at juntadeandalucia.es Cited by 1495 |
Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.
…, C Rodríguez, J Rodríguez-Martorell… - The Journal of …, 2004 - jrheum.org
OBJECTIVE: We carried out a prospective analysis of clinical and analytical findings in
individuals with antiphospholipid antibodies (aPL). METHODS: We prospectively studied 404 …
individuals with antiphospholipid antibodies (aPL). METHODS: We prospectively studied 404 …
Organellar proteomics of human platelet dense granules reveals that 14-3-3ζ is a granule protein related to atherosclerosis
…, A Sáez-Benito, J Rodríguez-Martorell… - Journal of proteome …, 2007 - ACS Publications
Dense granules, a type of platelet secretory organelle, are known to accumulate high
concentrations of small molecules such as calcium, adenine nucleotides, serotonin, pyrophosphate…
concentrations of small molecules such as calcium, adenine nucleotides, serotonin, pyrophosphate…
Hemofilia adquirida: epidemiología, clínica, diagnóstico y tratamiento
…, R Núñez, FJ Rodríguez-Martorell - Medicina Clínica, 2017 - Elsevier
El desarrollo de autoanticuerpos circulantes que inhiban a los factores de la coagulación
puede generar cuadros hemorrágicos graves y en ocasiones fatales. Esta entidad clínica se …
puede generar cuadros hemorrágicos graves y en ocasiones fatales. Esta entidad clínica se …
Documento multidisciplinar de consenso sobre el manejo de la hemorragia masiva. Primera actualización 2023 (documento HEMOMAS-II)
…, M Quintana, FJ Rodríguez-Martorell… - Revista Española de …, 2023 - Elsevier
El presente documento supone una puesta al día del documento multidisciplinar HEMOMAS,
publicado en el año 2016 con el aval de las Sociedades Científicas Españolas de …
publicado en el año 2016 con el aval de las Sociedades Científicas Españolas de …
Acquired haemophilia A: a review of what we know
…, FJ Rodríguez-Martorell… - Journal of Blood …, 2022 - Taylor & Francis
Autoantibodies against plasma coagulation factors could be developed by some individuals
inducing severe and sometimes fatal bleedings. This clinical entity is called acquired …
inducing severe and sometimes fatal bleedings. This clinical entity is called acquired …
Acquired haemophilia: Epidemiology, clinical presentation, diagnosis and treatment
…, R Núñez, FJ Rodríguez-Martorell - … Clínica (English Edition), 2017 - Elsevier
The development of circulating autoantibodies able to inhibit some coagulation proteins
induces severe or even life-threatening bleeding. This disorder is called acquired haemophilia. …
induces severe or even life-threatening bleeding. This disorder is called acquired haemophilia. …
Successful immune tolerance induction with a plasma-derived FVIII concentrate and intravenous immunoglobulins in a pediatric patient with congenital severe …
C de Cos, J Rodríguez-Martorell - Blood Coagulation & …, 2014 - journals.lww.com
We present the case of a pediatric patient born in July 1991, diagnosed with severe hemophilia
A at 8 months of life after a hemarthrosis. He was treated with regular factor replacement …
A at 8 months of life after a hemarthrosis. He was treated with regular factor replacement …
Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II)
…, M Quintana, FJ Rodríguez-Martorell… - Medicina Intensiva …, 2023 - Elsevier
This document is an update of the multidisciplinary document HEMOMAS, published in
2016 with the endorsement of the Spanish Scientific Societies of Anaesthesiology (SEDAR), …
2016 with the endorsement of the Spanish Scientific Societies of Anaesthesiology (SEDAR), …
[HTML][HTML] Biomarkers of venous thromboembolism recurrence after discontinuation of low molecular weight heparin treatment for cancer-associated thrombosis …
…, E García-Cabrera, FJ Rodríguez-Martorell… - Cancers, 2022 - mdpi.com
Simple Summary The duration of anticoagulant treatment for venous thromboembolism in
cancer patients is not well defined. The decision to suspend or re-introduce anticoagulation is …
cancer patients is not well defined. The decision to suspend or re-introduce anticoagulation is …
Differential biomarker profiles between unprovoked venous thromboembolism and cancer
…, MJ Castro-Pérez, FJ Rodríguez-Martorell… - Annals of …, 2020 - Taylor & Francis
Background The relationship between cancer and venous thromboembolic disease (VTD) are
complex because the activated coagulation factors are not only involved in thrombosis but …
complex because the activated coagulation factors are not only involved in thrombosis but …